Shanghai Cell Therapy Group
Shanghai Cell Therapy Group is a privately held Chinese cell therapy company that operates a vertically integrated value chain of cell drug development (CAR-T, DC vaccines), pharmaceutical-grade cell storage, tertiary oncology hospital services, and consumer cell-energy products, serving 80,000+ high-net-worth individuals, cancer and autoimmune patients, and enterprise partners across China and select international markets.
- Company typePrivate
- Founded2013
- HeadquartersJiading, China
- Headcount51–100
- GTM typeB2B and B2C
- OfferingServices
What Shanghai Cell Therapy Group does
Shanghai Cell Therapy Group is a privately held Chinese cell therapy company founded in 2013 and headquartered in Jiading District, Shanghai, with 501–1,000 employees. The company operates a vertically integrated full value chain spanning four business lines: cell drug development (CAR-T and DC vaccines), pharmaceutical-grade cell storage services, tertiary oncology medical services through Shanghai University Affiliated Mengchao Tumor Hospital and the newly opened Qinhuangdao Beidaihe New Area Hospital, and consumer cell-energy/wellness products under the Chenghuang brand.
The company's core technology stack centers on a proprietary non-viral JL gene writing system, the JL-Flash CAR-T™ manufacturing platform (reducing preparation time from 10–14 days to 6 hours and dose/cost by 5–30× versus conventional CAR-T), the VHHMAb® fourth-generation AI-powered nanobody discovery platform (patented in both China and the US), and the Jiliang targeted LNP delivery system. Its lead clinical assets include BZD1901 (self-secreting PD-1 nanobody armored mesothelin CAR-T, FDA Orphan Drug Designation), BZE2204 (triple-target CD19/CD22/BCMA Flash CAR-T with 100% ORR in r/r NHL IIT studies at 1/40 dose), and JL107/BaizeDC (armored DC tumor vaccine).
Commercially, the company generates revenue from premium cell storage subscriptions (80,000+ high-net-worth customers, ranked #1 in China with 49.19% market share in 2023), hospital and clinical services, enterprise B2B partnerships (Fosun Health, Bai Nian Insurance, Shanghai Anhui Chamber of Commerce), and consumer health products. It has raised approximately $333M across four funding rounds through 2021, is recognized as a Shanghai unicorn, and has filed 618+ patent applications globally. The group operates nine wholly-owned subsidiaries, including a US R&D subsidiary (Chantibody in Menlo Park) and an Australian partnership (AdAltA), supporting a deliberate internationalization path.
Shanghai Cell Therapy Group firmographics
Firmographics- Name
- Shanghai Cell Therapy Group
- Legal name
- 上海细胞治疗集团股份有限公司
- Website
- https://shcell.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Shanghai Cell Therapy Group is a privately held Chinese cell therapy company that operates a vertically integrated value chain of cell drug development (CAR-T, DC vaccines), pharmaceutical-grade cell storage, tertiary oncology hospital services, and consumer cell-energy products, serving 80,000+ high-net-worth individuals, cancer and autoimmune patients, and enterprise partners across China and select international markets.
- Ownership category
- akta.pro rank
Shanghai Cell Therapy Group industry classification
Industry- Product category
- Cell Therapy and Cellular Healthcare Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000), Services-Medical Laboratories (8071)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)
Keywords
Where Shanghai Cell Therapy Group is headquartered
LocationHeadquarters
- HQ city
- Jiading
- HQ country
- China
- HQ region
- Asia
Offices9 records
Markets served
Shanghai Cell Therapy Group business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Cell Drug Development and Sales: Development and commercialization of innovative cell therapy drugs including CAR-T products (BZE2204, BZD1901/BZDS1901), DC vaccines (BaizeDC/JL107), and nanobody-based therapies. Revenue from clinical development milestones, potential future drug product sales, and licensing of technology platforms. Products are advancing through clinical trials in China with international expansion underway.
- Cell Storage Services: Pharmaceutical-grade cell preservation services ('Baize Core Cell Chip' strategy) offering immune cell banking to high-net-worth individuals. Customers store young healthy cells for future therapeutic use. The company has ranked #1 in China's immune cell storage market by incremental volume and cumulative units from 2021-2023. Storage services generate recurring revenue from initial collection/processing fees and annual storage fees.
- Tumor Medical Services: Medical services through Shanghai University Affiliated Mengchao Tumor Hospital and the newly opened Qinhuangdao Beidaihe New Area Hospital. Provides immunotherapy-plus treatment, precision diagnostics, high-end health management, and comprehensive cancer care services generating revenue from medical service fees.
- Cell Energy Products (Chenghuang Series): Cell health and anti-aging products under the 'Chenghuang' brand including supplements, personal care products, and wellness offerings. Products have obtained Singapore HSA approval and are expanding internationally. Revenue from product sales through retail and B2B channels.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Cell storage service packages vary based on cell type, storage duration, and service level |
| Other | Multi-year contract | High-end health management and tumor medical services priced by service complexity |
Go-to-market motion2 records
Distribution channels7 records
Marketing channels8 records
Shanghai Cell Therapy Group product offering
Product offeringCore offering
Shanghai Cell Therapy Group is an integrated cell healthcare company operating across four pillars: (1) cell drug development including CAR-T and DC vaccine products in clinical trials, (2) pharmaceutical-grade immune cell storage and banking services, (3) tumor medical and immunotherapy-plus services through its own affiliated hospital and partner network, and (4) cell energy consumer health products under the Chenghuang brand. Its proprietary non-viral Flash CAR-T platform reduces CAR-T preparation time from 10–14 days to 6 hours.
Product overview
Shanghai Cell Therapy Group是一家以细胞科技为核心的创新型公司，构建细胞医疗健康全价值链体系。公司业务覆盖四大板块：细胞药物（含CAR-T、DC疫苗等创新细胞治疗产品）、细胞储存（白泽芯药品级细胞存储服务）、肿瘤医疗（上海大学附属孟超肿瘤医院及秦皇岛北戴河新区医院）、细胞充能（乘黄系列健康产品）。核心技术平台包括：JL-闪CAR-T™技术平台（6小时超快制备）、VHHMAb®第四代纳米抗体AI发现平台、JL基因写入系统、吉量精准递送系统。公司的白泽计划旨在实现60%肿瘤消退及60%老百姓用得起的细胞治疗。
Differentiator
Problem solved
Functional benefit
Brands
- 白泽计划 (Baize Plan): Cell therapy plan aimed at achieving 60% tumor regression and making advanced cell therapy accessible to 60% of Chinese population
- 吉量计划 (Jiliang Plan)
- 乘黄计划 (Chenghuang Plan)
- BaizeDC
- JL-闪CAR-T™
- VHHMAb®
- 白泽芯
Products and services
- Baize Core Cell Chip Pharmaceutical-Grade Cell Storage Service
- Shanghai University Affiliated Mengchao Tumor Hospital
- Qinhuangdao Beidaihe New Area Hospital
- Shanghai Baize Medical Laboratory
- BZ019 Non-viral CD19 CAR-T Cell Injection
- BZD1901 Self-Secreting PD-1 Nanobody Armored Mesothelin CAR-T
- BZE2204 Triple-Target Flash CAR-T (CD19/CD22/BCMA)
- BaizeDC (JL107) Nanobody-Armored DC Tumor Vaccine
- Chenghuang Series Cell Energy Health Products
- CT111 Trispecific Nanobody (PD-1×CTLA-4×VEGF)
- CT224 CDH17×CD3 T-Cell Engager (TCE)
Quantifiable outcome
- Flash CAR-T (BZE2204) achieved 100% ORR and ~70% CR in r/r NHL patients at 1/40 conventional dose without lymphodepletion conditioning
- +5 more outcomes
Companies that use Shanghai Cell Therapy Group
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles3 records
Shanghai Cell Therapy Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature8 records
Shanghai Cell Therapy Group partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- Fosun Health (复星健康科技集团)coreStrategic partnership signed on June 9, 2026 at the Qinhuangdao Beidaihe New Area Hospital. Both parties will jointly build the 'Baize Plan Advanced Cell Medical 产学研医 Innovation Collaboration Community', conduct joint clinical research on cell and gene therapies, and strengthen basic research and academic exchange. Fosun Health operates 19 hospitals with 6,500 beds and holds 5 GCP-certified institutions.
- Yangzhou University (扬州大学)minorCollaboration with Yangzhou University to develop the enhanced Baize (BZ) transposon system, results published in Nucleic Acids Research (IF=13.1).
- Chantibody Therapeutics Inc. (美国)coreUS-based subsidiary collaborating on 3 nanobody-based innovation drug research projects including CT111 (PD-1*CTLA-4*VEGF trispecific), CT224 (CD3/CDH17 TCE), and CARP AI platform. Located in Menlo Park, CA.
- Xinxiang Medical University (新乡医学院)minorHenan Cell Therapy Group jointly established the 'Henan Advanced Synthetic Bio-Medical and Clinical Innovation Translation Engineering Technology Research Center' with Xinxiang Medical University to strengthen synthetic biology research and clinical translation.
- Shanghai University (上海大学)coreCollaborative research published in Scientific Reports validating electroporation technology for preparing CAR-T from cryopreserved PBMCs. Joint development of Shanghai University Affiliated Mengchao Tumor Hospital and Shanghai University Cell Therapy Innovation Research Institute.
- Bai Nian Life Insurance (百年人寿保险)coreStrategic cooperation signed on February 14, 2025 to explore innovative models combining cell therapy with insurance services. The partnership aims to provide comprehensive health protection products and services to customers of both parties, integrating advanced cell technology with insurance protection.
- AdAltA (Australia)coreStrategic collaboration with Australian biotech company AdAltA to advance global clinical validation and market registration of BZD1901, marking the company's solid tumor CAR-T therapy entering international development stage.
- Shanghai University (上海大学)coreStrategic partnership共建 Shanghai University Affiliated Mengchao Tumor Hospital and Shanghai University Cell Therapy Innovation Research Institute. Goal to build an international first-class precision medical center and research-oriented tumor hospital.
- Shanghai Anhui Chamber of Commerce (上海市安徽商会)minorStrategic partnership to create a high-end medical service platform providing comprehensive health solutions including high-end medical care, health examinations, and full lifecycle health management for member entrepreneurs.
- Tongji University Affiliated East Hospital (同济大学附属东方医院)coreJoint establishment of Tongji-East Hospital Mengchao Tumor Hospital Cell Therapy Clinical and Basic Joint Research Center. Cooperates on IIT clinical trials, diagnostic kit clinical research, and medical device clinical research.
- University of Southern California (美国南加州大学)minor6-year strategic collaboration on 'In Vitro Expansion and Application of Hematopoietic Stem Cells and Progenitor Cells'. Company invested USD 3.6 million to fund USC research team led by Professor Ying Qilong, with company responsible for industrialization and commercialization.
- Wu Mengchao Nobel Laureate Medical Innovation Center (上海吴孟超联合诺贝尔奖获得者医疗科技创新中心)corePlatform established in collaboration with Nobel laureates for cutting-edge medical technology innovation, academic exchange, and cell technology R&D. Over 28 Nobel laureates have participated in exchanges and 15 serve as advisors.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
Shanghai Cell Therapy Group competitors and assessment
Company assessmentEmerging players
- Adagene: China-US clinical-stage biotech developing antibody-based therapeutics including TCEs; comparable in AI-driven antibody discovery and bispecific TCE approach intersecting with CT111/CT224 programs.
Direct peers
- Allogene Therapeutics: US-based allogeneic CAR-T platform company; comparable in CAR-T modality though using allogeneic rather than autologous approach, competing for similar indications in cell therapy.
- CARsgen Therapeutics: China-based CAR-T cell therapy company with multiple autologous CAR-T programs (including solid tumor CAR-T like zevorcabtagene autoleucel) — closest direct competitor in solid tumor and hematologic CAR-T development.
- Adaptimmune: Cell therapy company developing TCR-T therapies for solid tumors; comparable in engineered T-cell platform and solid tumor focus, though TCR-T rather than CAR-T.
- Cellular Biomedicine Group: China-US cell therapy company focused on CAR-T and regenerative medicine; comparable in cell therapy pipeline and cross-border development approach.
- JW Therapeutics: China-based CAR-T company with relma-cel (CD19 CAR-T) approved; directly comparable autologous CAR-T cell therapy developer competing in the same Chinese market and patient population.
- Legend Biotech: Nanjing Legend Biotech (sister to Genscript) developed cilta-cel (BCMA CAR-T) approved by FDA; a leading China-rooted CAR-T cell therapy developer directly comparable in modality and clinical-stage focus.
Broad incumbents
- Bristol Myers Squibb: Global oncology leader with approved CAR-T products (Breyanzi, Abecma) and broad cell therapy pipeline; major incumbent benchmark for autologous CAR-T commercialization, pricing, and global clinical development.
- BeiGene: Large Chinese biotech with oncology pipeline; broader incumbent operating across multiple therapeutic areas including cell therapy-adjacent biologics, with vastly greater scale and commercial reach.
- Fosun Pharmaceutical: Major Chinese pharmaceutical conglomerate and direct strategic partner of Shanghai Cell Therapy; operates hospital networks and biologics manufacturing that overlap with Shanghai Cell Therapy's clinical and commercial channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Shanghai Cell Therapy Group compliance and trust
Trust signalCompliance7 records
Shanghai Cell Therapy Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Shanghai Cell Therapy Group leadership team
Management profileNumber of profiles
Profiles11 records
Shanghai Cell Therapy Group subsidiaries and ownership
Company hierarchySubsidiaries9 records
Shanghai Cell Therapy Group funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Shanghai Cell Therapy Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Shanghai Cell Therapy Group
What does Shanghai Cell Therapy Group do?
Shanghai Cell Therapy Group is an integrated cell healthcare company operating across four pillars: (1) cell drug development including CAR-T and DC vaccine products in clinical trials, (2) pharmaceutical-grade immune cell storage and banking services, (3) tumor medical and immunotherapy-plus services through its own affiliated hospital and partner network, and (4) cell energy consumer health products under the Chenghuang brand. Its proprietary non-viral Flash CAR-T platform reduces CAR-T preparation time from 10–14 days to 6 hours.
Is Shanghai Cell Therapy Group a public or private company?
Shanghai Cell Therapy Group is a private company. It is classified as venture growth investor backed and is currently operating.
When was Shanghai Cell Therapy Group founded?
Shanghai Cell Therapy Group was founded in 2013. It employs 51 to 100 people.
Where is Shanghai Cell Therapy Group based?
Shanghai Cell Therapy Group is headquartered in Jiading, China, in the Asia region.
How does Shanghai Cell Therapy Group make money?
Four revenue lines are on record. Cell Drug Development and Sales are the primary driver. The others are cell Storage Services, tumor Medical Services and cell Energy Products (Chenghuang Series).
Who are Shanghai Cell Therapy Group's main competitors?
Adagene is listed as an emerging player. Direct peers are Allogene Therapeutics, CARsgen Therapeutics, Adaptimmune, Cellular Biomedicine Group, JW Therapeutics and Legend Biotech. Broad incumbents are Bristol Myers Squibb, BeiGene and Fosun Pharmaceutical.
Does Shanghai Cell Therapy Group have an API?
No public API is recorded for Shanghai Cell Therapy Group.
What industry is Shanghai Cell Therapy Group in?
Shanghai Cell Therapy Group's product category is Cell Therapy and Cellular Healthcare Services. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 541714 and its SIC code is 2836.